Insider Buying: Perspective Therapeutics (NYSEAMERICAN:CATX) Insider Purchases $29,400.00 in Stock

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) insider Markus Puhlmann bought 35,000 shares of the company’s stock in a transaction that occurred on Thursday, November 12th. The stock was acquired at an average price of $0.84 per share, for a total transaction of $29,400.00. Following the completion of the acquisition, the insider directly owned 178,542 shares in the company, valued at approximately $149,975.28. This represents a 24.38% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Markus Puhlmann also recently made the following trade(s):

• On Wednesday, November 11th, Markus Puhlmann bought 6,000 shares of Perspective Therapeutics stock. The shares were acquired at an average cost of $0.83 per share, with a total value of $4,980.00.

Perspective Therapeutics Stock Up 2.1%

CATX stock opened at $0.84 on Friday. Perspective Therapeutics, Inc. has a 12 month low of $0.78 and a 12 month high of $6.16. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 6.61. The firm has a 50 day simple moving average of $2.15 and a 200 day simple moving average of $3.45.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.06 million. Perspective Therapeutics had a negative return on equity of 42.25% and a negative net margin of 55,866.82%. On average, research analysts anticipate that Perspective Therapeutics, Inc. will post -1.01 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Commodore Capital LP acquired a new stake in shares of Perspective Therapeutics during the first quarter valued at approximately $26,424,000. Avidity Partners Management LP lifted its position in shares of Perspective Therapeutics by 88.4% in the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after acquiring an additional 2,839,266 shares in the last quarter. Affinity Asset Advisors LLC boosted its stake in Perspective Therapeutics by 954.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock worth $13,196,000 after purchasing an additional 2,864,582 shares during the period. Spruce Street Capital LP acquired a new position in Perspective Therapeutics in the 1st quarter worth approximately $10,955,000. Finally, Yu Fan purchased a new position in Perspective Therapeutics during the 1st quarter worth approximately $4,401,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on CATX shares. Wedbush reissued an “outperform” rating and set a $7.00 price objective (down from $9.00) on shares of Perspective Therapeutics in a research note on Tuesday. William Blair began coverage on Perspective Therapeutics in a research report on Friday, September 18th. They set an “outperform” rating on the stock. BMO Capital Markets reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a report on Friday, October 30th. BTIG Research reaffirmed a “buy” rating on shares of Perspective Therapeutics in a report on Monday, October 26th. Finally, Bank of America decreased their price target on Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Friday, August 14th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Perspective Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.10.

About Perspective Therapeutics

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.